Hospital-acquired pneumonia cost-effectiveness of therapy
|
Hospital-acquired pneumonia Microchapters |
|
Differentiating Hospital-Acquired Pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hospital-acquired pneumonia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hospital-acquired pneumonia cost-effectiveness of therapy |
|
FDA on Hospital-acquired pneumonia cost-effectiveness of therapy |
|
CDC onHospital-acquired pneumonia cost-effectiveness of therapy |
|
Hospital-acquired pneumonia cost-effectiveness of therapy in the news |
|
Blogs on Hospital-acquired pneumonia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Hospital-acquired pneumonia |
|
Risk calculators and risk factors for Hospital-acquired pneumonia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Linezolid was compared to vancomycin for the treatment of VAP, and showed cost-effectiveness as an alternative to vancomycin treatment as it had a higher cure rate and prices per treatment were similar.[1][2] One study reported that oropharingeal decontamination decreased the incidence of ventilator-associated pneumonia from 4% to less than 1% in the studied population. The cost of the intervention was less than $2500. [3]
References
- ↑ Shorr AF, Susla GM, Kollef MH (2004). "Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin". Crit Care Med. 32 (1): 137–43. doi:10.1097/01.CCM.0000104110.74657.25. PMID 14707572.
- ↑ De Cock E, Krueger WA, Sorensen S, Baker T, Hardewig J, Duttagupta S; et al. (2009). "Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany". Infection. 37 (2): 123–32. doi:10.1007/s15010-008-8046-7. PMID 19277465.
- ↑ van Nieuwenhoven CA, Buskens E, Bergmans DC, van Tiel FH, Ramsay G, Bonten MJ (2004). "Oral decontamination is cost-saving in the prevention of ventilator-associated pneumonia in intensive care units". Crit Care Med. 32 (1): 126–30. doi:10.1097/01.CCM.0000104111.61317.4B. PMID 14707570.